## NYSCF ID | Family Group | Relation | Sex | Age at Biopsy | Known Genotypes | Reprogramming Method | Status
---|---|---|---|---|---|---|---
051205-01-MR | 884 | Proband | M | 18 | Homozygous for common (1kb) deletion | mRNA | Available
051206-01-MR | 884 | Maternal | M | 48 | Heterozygous for common (1kb) deletion | mRNA | Available
051104-01-MR | 5003 | Maternal | F | 56 | Heterozygous for common (1kb) deletion | mRNA | Available
051105-01-MR | 5003 | Paternal | M | 59 | Wild-Type, Carrier E13 c.988>T, p.Val330Phe Mutation | mRNA | Available
051131-01-MR | 5003 | Proband | M | 57 | Wild-Type? No known mutation | mRNA | Available
051106-01-MR | 5009 | Maternal | F | 47 | Heterozygous for common (1kb) deletion | mRNA | Available
051111-01-MR | 5010 | Maternal | F | 48 | Heterozygous for common (1kb) deletion | mRNA | Available
051135-01-MR | 5010 | Proband | M | 13 | Heterozygous for common (1kb) deletion | mRNA | Available
05115-01-MR | 5014 | Paternal | M | 61 | Mutation confirmation pending | mRNA | Available
051116-01-MR | 5014 | Maternal | F | 56 | Mutation confirmation pending | mRNA | Available
051240-01-MR | 5020 | Maternal | F | 56 | Mutation confirmation pending | mRNA | Available
051242-01-MR | 5020 | Proband | M | 23 | Mutation confirmation pending | mRNA | Available
051090-01-MR | N/A | Proband | F | 46 | Heterozygous for common (1kb) deletion | mRNA | Available
051117-01-MR | N/A | Proband | M | 51 | Heterozygous for common (1kb) deletion | mRNA | Available

**NOTE:** Isogenic controls are in progress for the lines denoted with an asterisk (*). These lines are a work in progress and estimated availability dates for the isogenic controls will be updated on this table once the edit has been confirmed and the cells are in final expansion and QC.

**NOTE:** Genotypes are confirmed by NYSCF by sequencing. All samples are genotyped with primer sets that detect the common 1kb deletion. In some samples, we additionally genotyped for status of other known mutations.

**NOTE:** Culture conditions: iPSC lines are derived and cultured under feeder-free conditions (see Paull D et al, Nature Methods 2015). Full culture protocol details will be provided along with the cells distributed. Cell lines are available upon request and subject to a fully executed MTA before shipment.